Catridecacog
id:
catridecacog-317-17445197
title:
Catridecacog
text:
Catridecacog, sold under the brand name Tretten in the US and NovoThirteen in the EU) is a class of recombinant factor XIII A-subunit based biopharmaceutical medicine, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency, which is a kind of Factor XIII deficiency. The medication prevents bleeding in patients with this condition, and has been approved by the U.S. Food and Drug Administration (FDA) for this use in the US in 2014. It was brought to market
brand slug:
wiki
category slug:
encyclopedia
description:
Genetically engineered medicine
original url:
https://en.wikipedia.org/wiki/Catridecacog
date created:
date modified:
2023-11-30T18:56:20Z
main entity:
{"identifier":"Q16858452","url":"https://www.wikidata.org/entity/Q16858452"}
image:
fields total:
13
integrity:
14